Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.
The investigators will enroll patients with new/transformed hematologic malignancies. The investigators will follow the patients until the end of the study, report their survival at one year and examine their prognosis.
Study Type
OBSERVATIONAL
Enrollment
300
Meir Medical Center
Kfar Saba, Israel
RECRUITINGRabin Medical Center
Petah Tikva, Israel
RECRUITINGTo assess 365 days mortality of OHI+ and OHI- patients
The investigators will use Kaplan-Meier curves to compare survival between OHI+ and OHI- patients
Time frame: Mortality rate one year from OHI assessment
To determine the incidence of OHI+ patients in our cohort
The investigators will assess the incidence of OHI+ within our cohort (OHI+/total patients enrolled)
Time frame: The investigators will assess the incidence after three years of enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.